Search Results

jCyte, Inc. Announces Positive Pre-Phase 3 FDA Type B Meeting and Outlines Plans to Start Pivotal Trial of jCell ® for Retinitis Pigmentosa in the Second Half of 2024.

The Center for Breakthrough Medicines (CBM) and jCyte today announced a multi-year manufacturing agreement wherein CBM will be the primary manufacturer of jCyte’s U.S. Food & Drug Administration’s Regenerative Medicine Advanced Therapy (RMAT) designated cell therapy, jCell.

jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the expansion of the company’s leadership team with the appointment of Dr. Stewart Craig as Chief Technology Officer.

jCyte, Inc. today announced the expansion of the role of Dr. Samir Mody. In addition to his Chief Commercial Officer responsibilities focused on preparing for the North American launch of jCell, Dr. Mody will now also assume leadership for the Global Pricing, Health Economics, and Reimbursement functions for jCyte.

jCyte, Inc . announced the continued expansion of the company’s executive management team with the appointment of Adrian Morris as Chief Development Officer.

jCyte, Inc. , a biotech company dedicated to improving the lives of patients with retinal degenerative diseases, today announced the further expansion of the company’s executive management team with the appointment of John Sholar as General Counsel. Mr. Sholar brings to jCyte more than 20 years of industry experience, serving as the head of North American legal

jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the company’s executive management team with the appointment of John Pollack, MD, FASRS, as the company’s first Chief Medical Officer (CMO).

jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the Company’s leadership team with the appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations.

jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the company’s leadership team with the appointment of Peter Kuper as Senior Vice President of Finance and Information Technology.

jCyte, Inc. announced the further expansion of the company’s executive management team with the appointment of Adam Walsh, M.D. as Chief Financial Officer.